President Trump’s term in office approached its end last week with a crowd of rioters sieging Capitol Hill. Although the episode ended in a few hours, it laid bare the tensions that have made the past four years so unpredictable. The scenes were troubling to watch,
This is the last issue of WeekWatch in 2020. We’ll resume service on Monday 11 January. Until then, we hope that you and your families have an enjoyable, safe and restful break, and we wish you the best for next year and beyond. Uncertainty made a
“Despite the fact that deadlines have been missed over and over, we think it is responsible at this point to go the extra mile,” read a joint statement yesterday from European Commission President Ursula von der Leyen and UK Prime Minister Boris Johnson. Details were thin
After the flurry of vaccine breakthroughs in recent weeks, and with 2020 drawing to a close, investors are focusing on the shape of the economic recovery that they expect to take place in 2021. Last week, the OECD published its twice-yearly economic outlook for countries around
Global markets are on track for their best month ever, after the announcement of several vaccines to fight COVID-19 and the election of Joe Biden shifted market sentiment to ‘risk-on.’ The US Dow Jones hit a record high last week and the MSCI World index
Vaccine announcements proved themselves to be like buses last week, after two arrived in quick succession. Moderna announced that its phase three clinical trials found its vaccine to be 95% effective, just one week after Pfizer/BioNTech had announced their results. Early this week, University of Oxford/AstraZeneca
Six countries, 44,000 trial participants, 90% effective: the numbers in Pfizer’s press release last week were promising. On Monday, the US drug giant announced that the late-stage trial of its COVID-19 vaccine, being co-produced with Germany’s BioNTech, had produced some strong results. The news fuelled a
88/89 Whiting Street
Bury St Edmunds
Suffolk, IP33 1NX
01284 703422
abbeygatewm@sjpp.co.uk
Registered in England and Wales
Company No.06803554
The Partner Practice is an Appointed Representative of and represents only St. James's Place Wealth Management plc (which is authorised and regulated by the Financial Conduct Authority) for the purpose of advising solely on the Group’s wealth management products and services, more details of which are set out on the Group’s website www.sjp.co.uk/products. The ‘St. James's Place Partnership’ and the titles ‘Partner’ and ‘Partner Practice’ are marketing terms used to describe St. James's Place representatives.